While the company has clearly experienced setbacks during the year, we continue to believe the shares remain undervalued with a current NAV of 109p. Our trough NAV of c45p assumes current asset values with peak 2018 net debt and does not include any benefit of future growth. Even on this highly conservative measure, the shares are trading at a discount. We believe this provides support and see significant long term value at current levels backed with a robust mature business and a sound long
02 May 2017
An accurate diagnosis: financial results as expected
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
An accurate diagnosis: financial results as expected
Cambridge Nutritional Sciences PLC (CNSL:LON) | 3.8 0 (-3.8%) | Mkt Cap: 9.16m
- Published:
02 May 2017 -
Author:
Martin Hall -
Pages:
4
While the company has clearly experienced setbacks during the year, we continue to believe the shares remain undervalued with a current NAV of 109p. Our trough NAV of c45p assumes current asset values with peak 2018 net debt and does not include any benefit of future growth. Even on this highly conservative measure, the shares are trading at a discount. We believe this provides support and see significant long term value at current levels backed with a robust mature business and a sound long